利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.02 秒)

    Combined treatment with irinotecan and an epidermal growth factor receptor kinase inhibitor
    2.
    发明申请
    Combined treatment with irinotecan and an epidermal growth factor receptor kinase inhibitor 审中-公开
    伊立替康和表皮生长因子受体激酶抑制剂联合治疗

    公开(公告)号：US20050272737A1

    公开(公告)日：2005-12-08

    申请号：US11144855

    申请日：2005-06-03

    申请人： Jianping Chen ,  Brian Higgins ,  Kenneth Kolinsky

    发明人： Jianping Chen ,  Brian Higgins ,  Kenneth Kolinsky

    IPC分类号： A61K31/4706 ,  A61K31/4745 ,  A61K31/498 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K39/395 ,  A61K45/06

    CPC分类号： A61K31/519 ,  A61K31/4706 ,  A61K31/4745 ,  A61K31/517 ,  A61K31/5377 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and irinotecan combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and irinotecan combination in combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as Tarceva™).

    摘要翻译： 本发明提供了一种用于治疗患者的肿瘤或肿瘤转移的方法，其包括向所述患者同时或相继施用治疗有效量的EGFR激酶抑制剂和伊立替康组合，所述另外的药物或治疗剂， 癌症药物或放射治疗。 本发明还包括由EGFR激酶抑制剂和伊立替康组合与药学上可接受的载体组合的药物组合物。 可用于实施本发明的EGFR激酶抑制剂的优选实例是化合物厄洛替尼HCl（也称为Tarceva TM）。

    Combined treatment with cisplatin and an epidermal growth factor receptor kinase inhibitor
    4.
    发明申请
    Combined treatment with cisplatin and an epidermal growth factor receptor kinase inhibitor 有权
    联合治疗顺铂和表皮生长因子受体激酶抑制剂

    公开(公告)号：US20050271747A1

    公开(公告)日：2005-12-08

    申请号：US11145495

    申请日：2005-06-03

    申请人： Brian Higgins ,  Kenneth Kolinsky

    发明人： Brian Higgins ,  Kenneth Kolinsky

    IPC分类号： A61K31/4706 ,  A61K31/496 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K33/24 ,  A61K38/50

    CPC分类号： A61K31/519 ,  A61K31/4706 ,  A61K31/496 ,  A61K31/517 ,  A61K31/5377 ,  A61K33/24 ,  A61K38/50 ,  A61K2300/00

    摘要： The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and cisplatin combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and cisplatin combination in combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as Tarceva™).

    摘要翻译： 本发明提供了一种用于治疗患者的肿瘤或肿瘤转移的方法，其包括向所述患者同时或依次施用治疗有效量的EGFR激酶抑制剂和顺铂组合，所述另外的药物或治疗剂， 癌症药物或放射治疗。 本发明还包括药物组合物，其由EGFR激酶抑制剂和顺铂组合与药学上可接受的载体组合组成。 可用于实施本发明的EGFR激酶抑制剂的优选实例是化合物厄洛替尼HCl（也称为Tarceva TM）。

    Combined treatment with gemcitabine and an epidermal growth factor receptor kinase inhibitor
    6.
    发明申请
    Combined treatment with gemcitabine and an epidermal growth factor receptor kinase inhibitor 审中-公开
    吉西他滨联合治疗和表皮生长因子受体激酶抑制剂

    公开(公告)号：US20050272688A1

    公开(公告)日：2005-12-08

    申请号：US11144952

    申请日：2005-06-03

    申请人： Brian Higgins ,  Kenneth Kolinsky

    发明人： Brian Higgins ,  Kenneth Kolinsky

    IPC分类号： A61K31/4706 ,  A61K31/498 ,  A61K31/513 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/7072

    CPC分类号： A61K31/519 ,  A61K31/4706 ,  A61K31/498 ,  A61K31/513 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/7072 ,  A61K2300/00

    摘要： The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and gemcitabine combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and gemcitabine combination in combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as Tarceva™).

    摘要翻译： 本发明提供了一种用于治疗患者的肿瘤或肿瘤转移的方法，其包括向所述患者同时或依次给予治疗有效量的EGFR激酶抑制剂和吉西他滨组合，所述组合具有或不含另外的药物或治疗剂， 癌症药物或放射治疗。 本发明还包括由EGFR激酶抑制剂和吉西他滨组合与药学上可接受的载体组合的药物组合物。 可用于实施本发明的EGFR激酶抑制剂的优选实例是化合物厄洛替尼HCl（也称为Tarceva TM）。

    Combined treatment with cisplatin and an epidermal growth factor receptor kinase inhibitor
    7.
    发明授权
    Combined treatment with cisplatin and an epidermal growth factor receptor kinase inhibitor 有权
    联合治疗顺铂和表皮生长因子受体激酶抑制剂

    公开(公告)号：US07951405B2

    公开(公告)日：2011-05-31

    申请号：US11145495

    申请日：2005-06-03

    申请人： Brian Higgins ,  Kenneth Kolinsky

    发明人： Brian Higgins ,  Kenneth Kolinsky

    IPC分类号： A61K33/24 ,  A61K31/517

    CPC分类号： A61K31/519 ,  A61K31/4706 ,  A61K31/496 ,  A61K31/517 ,  A61K31/5377 ,  A61K33/24 ,  A61K38/50 ,  A61K2300/00

    摘要： The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and cisplatin combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and cisplatin combination in combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as Tarceva™).

    摘要翻译： 本发明提供了一种用于治疗患者的肿瘤或肿瘤转移的方法，其包括向所述患者同时或依次施用治疗有效量的EGFR激酶抑制剂和顺铂组合，所述另外的药物或治疗剂， 癌症药物或放射治疗。 本发明还包括药物组合物，其由EGFR激酶抑制剂和顺铂组合与药学上可接受的载体组合组成。 可用于实施本发明的EGFR激酶抑制剂的优选实例是化合物厄洛替尼HCl（也称为Tarceva TM）。

    COMBINATION THERAPY
    9.
    发明申请
    COMBINATION THERAPY 有权
    组合治疗

    公开(公告)号：US20120148533A1

    公开(公告)日：2012-06-14

    申请号：US13313042

    申请日：2011-12-07

    申请人： Kapil Dhingra ,  Brian Higgins ,  Kenneth Kolinsky ,  Richard J. Lee ,  Brian Lestini ,  Kathryn Packman ,  Fei Su

    发明人： Kapil Dhingra ,  Brian Higgins ,  Kenneth Kolinsky ,  Richard J. Lee ,  Brian Lestini ,  Kathryn Packman ,  Fei Su

    IPC分类号： A61K38/21 ,  A61P35/00

    CPC分类号： A61K38/212 ,  A61K31/437 ,  A61K38/21 ,  A61K2300/00

    摘要： The present invention relates to a combination therapy of propane-1-sulfonic acid{3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl-2,4-difluoro-phenyl]-amide}, or a pharmaceutically acceptable salt thereof, and an interferon for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer. In particular, the present invention relates to such a therapy wherein the interferon is peginterferon alfa-2a and the disorder is melanoma containing the V600E b-Raf mutation.

    摘要翻译： 本发明涉及丙烷-1-磺酸{3- [5-（4-氯 - 苯基）-1H-吡咯并[2,3-b]吡啶-3-羰基-2,4-二氟 - 苯基] - 酰胺}或其药学上可接受的盐，以及用于治疗患有增殖性疾病，特别是实体瘤例如结肠直肠癌，黑素瘤和甲状腺癌的患者的干扰素。 特别地，本发明涉及这样的治疗，其中干扰素是聚乙二醇化干扰素α-2a，该病症是含有V600E b-Raf突变的黑素瘤。